Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Canellos

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2006
Where does hematology end and oncology begin? Questions of professional boundaries and medical authorityGretchen Krueger, George Canellos
Leukemia & Lymphoma|September 13, 2006
Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906Sonali M Smith, Jeffrey L Johnson, Donna Niedzwiecki, et al.
Leukemia & Lymphoma|February 28, 2007
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901Myron S Czuczman, Pierluigi Porcu, Jeffrey Johnson, et al.
Haematologica|December 3, 2011
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtypeWyndham H Wilson, Sin-Ho Jung, Pierluigi Porcu, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2006
Where does hematology end and oncology begin? Questions of professional boundaries and medical authorityGretchen Krueger, George Canellos
Leukemia & Lymphoma|September 13, 2006
Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906Sonali M Smith, Jeffrey L Johnson, Donna Niedzwiecki, et al.
Leukemia & Lymphoma|February 28, 2007
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901Myron S Czuczman, Pierluigi Porcu, Jeffrey Johnson, et al.
Haematologica|December 3, 2011
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtypeWyndham H Wilson, Sin-Ho Jung, Pierluigi Porcu, et al.
Pageof 1